{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:11Z","timestamp":1787026931685,"version":"build-2736575974"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progressive multifocal leukoencephalopathy (PML) is a rare and often lethal brain disorder caused by the common, typically benign polyomavirus 2, also known as JC virus (JCV). In a small percentage of immunosuppressed individuals, JCV is reactivated and infects the brain, causing devastating neurological defects. A wide range of immunosuppressed groups can develop PML, such as patients with: HIV\/AIDS, hematological malignancies (e.g., leukemias, lymphomas, and multiple myeloma), autoimmune disorders (e.g., psoriasis, rheumatoid arthritis, and systemic lupus erythematosus), and organ transplants. In some patients, iatrogenic (i.e., drug-induced) PML occurs as a serious adverse event from exposure to immunosuppressant therapies used to treat their disease (e.g., hematological malignancies and multiple sclerosis). While JCV infection and immunosuppression are necessary, they are not sufficient to cause PML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We hypothesized that patients may also have a genetic susceptibility from the presence of rare deleterious genetic variants in immune-relevant genes (e.g., those that cause inborn errors of immunity). In our prior genetic study of 184 PML cases, we discovered 19 candidate PML risk variants. In the current study of another 152 cases, we validated 4 of 19 variants in both population controls (gnomAD 3.1) and matched controls (JCV+ multiple sclerosis patients on a PML-linked drug \u2265 2 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The four variants, found in immune system genes with strong biological links, are:\n                      <jats:italic>C8B<\/jats:italic>\n                      , 1-57409459-C-A, rs139498867;\n                      <jats:italic>LY9<\/jats:italic>\n                      (alias\n                      <jats:italic>SLAMF3<\/jats:italic>\n                      ), 1-160769595-AG-A, rs763811636;\n                      <jats:italic>FCN2<\/jats:italic>\n                      , 9-137779251-G-A, rs76267164;\n                      <jats:italic>STXBP2<\/jats:italic>\n                      , 19-7712287-G-C, rs35490401. Carriers of any one of these variants are shown to be at high risk of PML when drug-exposed PML cases are compared to drug-exposed matched controls: P value = 3.50E-06, OR = 8.7 [3.7\u201320.6]. Measures of clinical validity and utility compare favorably to other genetic risk tests, such as\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      screening for breast cancer risk and HLA-B\n                      <jats:sup>*<\/jats:sup>\n                      15:02 pharmacogenetic screening for pharmacovigilance of carbamazepine to prevent Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For the first time, a PML genetic risk test can be implemented for screening patients taking or considering treatment with a PML-linked drug in order to decrease the incidence of PML and enable safer use of highly effective therapies used to treat their underlying disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.1016377","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T04:49:27Z","timestamp":1670993367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Eli","family":"Hatchwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shapour","family":"Jalilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Taoufik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houria","family":"Hendel-Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Oksenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Gasnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rancour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor J.","family":"Koralnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene O.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy S.","family":"Eis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2018001","DOI":"10.4178\/epih.e2018001","article-title":"Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica","volume":"40","author":"Paz","year":"2018","journal-title":"Epidemiol Health."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00415-018-8813-z","article-title":"Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration","volume":"265","author":"Aoyama","year":"2018","journal-title":"J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3988\/jcn.2019.15.4.454","article-title":"High seroprevalence and index of anti-john-cunningham virus antibodies in korean patients with multiple sclerosis","volume":"15","author":"Kim","year":"2019","journal-title":"J Clin Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2055217318788699","DOI":"10.1177\/2055217318788699","article-title":"High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis","volume":"4","author":"Lau","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/v11100930","article-title":"Novel polyomaviruses in mammals from multiple orders and reassessment of polyomavirus evolution and taxonomy","volume":"11","author":"Ehlers","year":"2019","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00705-016-2794-y","article-title":"Moens U, Ramqvist T, et al. A taxonomy update for the family Polyomaviridae","volume":"161","author":"Feltkamp","year":"2016","journal-title":"Arch Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00415-021-10952-5","article-title":"Innovative therapeutic concepts of progressive multifocal leukoencephalopathy","volume":"269","author":"Mohn","year":"2022","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","article-title":"Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders","volume":"107","author":"Yang","year":"2020","journal-title":"J Leukoc Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.sder.2010.01.001","article-title":"Assessing long-term drug safety: lessons (re) learned from raptiva","volume":"29","author":"Seminara","year":"2010","journal-title":"Semin Cutan Med Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on adverse reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","article-title":"Sorting out the risks in progressive multifocal leukoencephalopathy","volume":"11","author":"Calabrese","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ejh.13751","article-title":"Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies","volume":"108","author":"Diamantopoulos","year":"2022","journal-title":"Eur J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/acn3.51130","article-title":"Improving risk-stratification of natalizumab-associated PML","volume":"8","author":"Tugemann","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17562864211039648","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s00415-018-8996-3","article-title":"Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients","volume":"265","author":"Baber","year":"2018","journal-title":"J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2174\/1570159X19666211111123202","article-title":"Changes in john cunningham virus index in multiple sclerosis patients treated with different disease-modifying therapies","volume":"20","author":"Sgarlata","year":"2022","journal-title":"Curr Neuropharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ana.25437","article-title":"Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients","volume":"85","author":"Dalla Costa","year":"2019","journal-title":"Ann Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1212\/NXI.0000000000001003","article-title":"Serum neurofilament levels and PML risk in patients with multiple sclerosis treated with natalizumab","volume":"8","author":"Fissolo","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fimmu.2015.00216","article-title":"Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?","volume":"6","author":"Hatchwell","year":"2015","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","article-title":"Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird's eye view","volume":"9","author":"Mills","year":"2018","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clim.2016.08.002","article-title":"Novel mutation in DOCK8-HIES with severe phenotype and successful transplantation","volume":"178","author":"Al Shekaili","year":"2017","journal-title":"Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/archneur.64.2.273","article-title":"X-linked hyper-IgM syndrome associated with a rapid course of multifocal leukoencephalopathy","volume":"64","author":"Aschermann","year":"2007","journal-title":"Arch Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10875-014-0114-4","article-title":"Whole genome sequencing reveals a chromosome 9p deletion causing DOCK8 deficiency in an adult diagnosed with hyper IgE syndrome who developed progressive multifocal leukoencephalopathy","volume":"35","author":"Day-Williams","year":"2015","journal-title":"J Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10875-014-0116-2","article-title":"Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease","volume":"35","author":"Dhalla","year":"2015","journal-title":"J Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/archopht.119.9.1376","article-title":"Visual loss due to progressive multifocal leukoencephalopathy in a congenital immunodeficiency disorder","volume":"119","author":"Downes","year":"2001","journal-title":"Arch Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaci.2014.12.1945","article-title":"The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency","volume":"136","author":"Engelhardt","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10875-018-0578-8","article-title":"Progressive multifocal leukoencephalopathy in primary immunodeficiencies","volume":"39","author":"Hadjadj","year":"2019","journal-title":"J Clin Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jaci.2019.11.051","article-title":"Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations","volume":"146","author":"Lorenzini","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s10875-020-00862-y","article-title":"Long-term survival after progressive multifocal leukoencephalopathy in a patient with primary immune deficiency and NFKB1 mutation","volume":"40","author":"Marechal","year":"2020","journal-title":"J Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","article-title":"Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis","volume":"131","author":"Sampaio","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2016.12.013","article-title":"Evaluation of RAG1 mutations in an adult with combined immunodeficiency and progressive multifocal leukoencephalopathy","volume":"179","author":"Schr\u00f6der","year":"2017","journal-title":"Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s10875-021-01139-8","article-title":"Late-onset progressive multifocal leukoencephalopathy (PML) and lymphoma in a 65-year-old patient with XIAP deficiency","volume":"41","author":"Seguier","year":"2021","journal-title":"J Clin Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2169\/internalmedicine.45.6023","article-title":"Progressive multifocal leukoencephalopathy complicating X-linked hyper-IgM syndrome in an adult","volume":"45","author":"Suzuki","year":"2006","journal-title":"Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/00365540310016673","article-title":"Progressive multifocal leukoencephalopathy in a patient with X-linked agammaglobulinemia","volume":"35","author":"Teramoto","year":"2003","journal-title":"Scand J Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","article-title":"The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee","volume":"41","author":"Tangye","year":"2021","journal-title":"J Clin Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fneur.2020.00186","article-title":"Germline genetic risk variants for progressive multifocal leukoencephalopathy","volume":"11","author":"Eis","year":"2020","journal-title":"Front Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/genetics\/155.2.945","article-title":"Inference of population structure using multilocus genotype data","volume":"155","author":"Pritchard","year":"2000","journal-title":"Genetics."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.cell.2018.09.049","article-title":"Low-frequency and rare-coding variation contributes to multiple sclerosis risk","volume":"175","year":"2018","journal-title":"Cell"},{"key":"B50","first-page":"1","article-title":"Statistical algorithms in review manager 5","author":"Deeks","year":"2010","journal-title":"Statistical Methods Group of The Cochrane Collaboration"},{"key":"B51","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/tpj.2016.34","article-title":"Maitland-van der Zee AH, Janssens A. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies","volume":"17","author":"Tonk","year":"2017","journal-title":"Pharmacogenom J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","volume":"1","author":"Kurian","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/1873-3468.13856","article-title":"The imitation game: a viral strategy to subvert the complement system","volume":"594","author":"Agrawal","year":"2020","journal-title":"FEBS Lett."},{"key":"B58","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s13238-012-2924-6","article-title":"Complement genetics, deficiencies, and disease associations","volume":"3","author":"Mayilyan","year":"2012","journal-title":"Protein Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/v13050824","article-title":"Complement proteins as soluble pattern recognition receptors for pathogenic viruses","volume":"13","author":"Murugaiah","year":"2021","journal-title":"Viruses"},{"key":"B60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00281-021-00892-7","article-title":"Tipping the balance: intricate roles of the complement system in disease and therapy","volume":"43","author":"Pouw","year":"2021","journal-title":"Semin Immunopathol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/JLB.2MR1018-413R","article-title":"Viral CD229 (Ly9) homologs as new manipulators of host immunity","volume":"105","author":"Angulo","year":"2019","journal-title":"J Leukoc Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2014.00167","article-title":"Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning","volume":"5","author":"Sieni","year":"2014","journal-title":"Front Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fimmu.2016.00004","article-title":"Responses to microbial challenges by SLAMF receptors","volume":"7","author":"van Driel","year":"2016","journal-title":"Front Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1212\/NXI.0000000000000559","article-title":"Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?","volume":"6","author":"Nakahara","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2019","journal-title":"Mult Scler."},{"key":"B68","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12974-020-01865-7","article-title":"Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod","volume":"17","author":"Watanabe","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/cpt.2347","article-title":"Evidence, in context: a regulatory perspective on pharmacogenetics","volume":"111","author":"Pacanowski","year":"2022","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1016377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T04:49:32Z","timestamp":1670993372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1016377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":69,"alternative-id":["10.3389\/fneur.2022.1016377"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1016377","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1016377"}}